Skip to content

Author

Daniel Weintraub

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Apathy in Lewy Body Disorders: A Position Paper.

Apathy is one of the most prevalent and disabling non-motor symptoms in Parkinson's disease (PD) and dementia with Lewy bodies (DLB), collectively referred to as Lewy body disorders (LBDs). It is associated with reduced quality of life, accelerated cognitive decline, increased caregiver burden, and poorer functional ou...

J. Kulisevsky, Lidia Bojtos, M. Kramberger et al. · 0 citations
Open access Aug 2026

Meditation and breathwork on anxiety in Parkinson's disease: A pilot randomized controlled trial

Background Anxiety and other non-motor symptoms can greatly diminish quality of life in people with Parkinson's Disease (PD). Yet, few randomized controlled trials (RCTs) have assessed accessible, non-pharmacological mental health treatments for people with PD. Objective To assess the feasibility and impact of brief, r...

Akila Rayapuraju, Preeti U Reed, Jennifer Liu et al. · 0 citations
Review Open access Sep 2026

Cognition endpoints for Parkinson's disease: A roadmap for developing patient-focused assessment tools to accelerate drug development

Cognitive dysfunction is a prevalent and impactful feature of Parkinson's disease (PD), with substantial heterogeneity in onset, severity, and progression, and a high lifetime risk of dementia. Despite its clinical importance, effective treatments and fit-for-purpose outcome measures remain limited. This article report...

Chris J. Edgar, Kathleen L. Poston, Cheryl D. Coon et al. · 0 citations
Open access Sep 2026

Utilizing intraindividual cognitive variability to predict progression in stage 2 neuronal synuclein disease.

OBJECTIVE Neuronal synuclein disease (NSD) involves pathological α-synuclein presence and often dopaminergic dysfunction, initially preceding overt clinical symptoms. NSD-Integrated Staging System identifies Stage 2A (no dopaminergic dysfunction) and 2B (dopaminergic dysfunction) as prodromal phases marked by subtle cl...

Hannah L. Combs, R. Kurth, A. Nair et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.